NGM·Healthcare·$452M·#206 / 520 in Healthcare
VNDA Vanda Pharmaceuticals Inc.
51SPECULATIVE
CATEGORY BREAKDOWN
GROWTH14
QUALITY60
STABILITY50
VALUATION95
GOVERNANCE60
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+8.7%
14
> 50% strong
Gross Margin
Revenue retained after direct costs
94.0%
100
> 50% strong
Cash Runway
Months of cash at current burn rate
9 months
27
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
3.9%
97
< 25% strong
Price / Sales
Market cap relative to trailing revenue
2.1x
95
< 3x strong
Rule of 40
Growth rate plus operating margin
-61
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
6.2%
46
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+2.0%
88
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE VNDA WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when VNDA's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.